Thirty-four patients who had undergone bone marrow transplantation (BMT) were examined; 83.3% of those who received single shot and none of those who received fractionated total body irradiation (TBI) developed cataracts. The use of steroids to treat chronic Graft Versus Host Disease (GVHD) produced more severe cataracts in those who had allogeneic transplants after single shot TBI, but follow-up has not been long enough to assess their effect following fractionated TBI. Keratocon junctivitis sicca (KeS) was seen in 81.8% of patients with chronic GVHD and in 33.3% of patients after autologous BMT.
Bone marrow transplantation is now well recognised as a treatment for aplastic anaemia and severe haematological malignancy. Patients either receive autologous marrow taken whilst in remission and stored for rein fusion at a later date, or donor marrow from a tissue matched relative or a matched but unre lated donor. Prior to infusion of the marrow, the patients receive high-dose chemotherapy alone or in combination with TBI to eradicate all host malignant tissue and minimise rejec tion of the donor marrow. The major non infective complication of allogeneic BMT is Graft Versus Host Disease which affects prin cipally the skin, eyes and GI tract and may be fatal. The aim of this study was to investigate the ocular complications of BMT and chronic GYHD.
Patients and Methods
Between March 1983 and February 1988,68 BMTs were performed on 63 patients in Car diff. Included are 23 patients who received autologous marrow, three having double autotransplants, 40 undergoing allogeneic BMT, two having double transplantation. At the time of the study, 34 patients were avail able for evaluation. Of these, twelve received autologous marrow: five males aged 19-56 years (mean 40 years) and seven females aged 24-61 years (mean 45.1 years). The three double autotransplants were performed on males aged 19 and 23 years as planned pro cedures and one female aged 24 years for relapsed acute myeloid leukaemia (AML). A further 22 patients received allogeneic mar row: fourteen males aged 12-45 years (mean 28.3 years) and eight females aged 19-49 years (mean 36.75 years). One male aged 29 years underwent two allogeneic BMTs for relapsed chronic myeloid leukaemia (CML).
Informed consent was obtained from all patients who underwent an ophthalmic exam ination including best corrected visual acuity for both near and distance, assessment of the pre-corneal tear film and extent of con junctival and corneal staining with Rose Ben gal. The lens and fundus were examined after pupillary dilation with one per cent Trop icamide. Schirmers test was performed and the extent of cataract formation graded according to Crews' classification.l
Results
(1) Autologous BMT There were twelve patients in this group (Table I) . Of nine patients receiving TBI, five were given 950 cGy as a single shot and four were given fractioned radiation of five frac tions to a total dose of 1125 cGy. Of the three patients who underwent two BMTs, two received single shot and one fractionated TBI, all at the time of the second transplant.
Cataracts developed in four patients who received single shot TBI. Of these, three patients had Grade I posterior subcapsular lens opacities (PSCLO), the time of examin ation varying between 23 and 42 months post transplantation, and one patient had Grade II PSCLO 29 months post BMT, having taken steroids for three months for oral bleeding. Another patient after single shot TBI had no cataract after 22 months follow-up, and one patient (aged 61 years) who had no TBI and no steroids had Grade I PSCLO. None of these patients complained of any visual diffi culties. Within a follow-up period of 9 to 18 months, no cataracts were detected in the four patients who received fractionated TBI.
Only one patient (Patient 2) complained of symptoms suggestive of dry eye which were relieved by artificial tear drops prescribed by her General Practitioner, but this was not con- (Table II) : 18 receiving TBI, 12 given as a single shot, five fractionated and the patient who underwent double transplantation had single shot before his first transplant and fractionated before the second. The total dose of radiation was the same as for autologous BMT. Chronic GVHD developed in 11 of the 22 patients (50% ), all but one of these having been preceded by acute GVHD. Within this group, seven of the patients received single shot, two fractionated and two no TBI. Another nine patients (four single shot, three fractionated, one none and one both) suffered acute GVHD, but with no signs of chronic GCHD up to the time of the study, Of the thirteen patients who received single shot TBI (including the patient who had both), one had Grade III and ten Grade IV PSCLO after follow-up of 26-63 months, The other two had no evidence of cataracts (fol low-up 20 and 23 months), None of those receiving fractionated TBI had any evidence of cataract formation (follow-up 4-12 months), Seven of the patients with Grade III or IV PSCLO had suffered chronic GVHD needing treatment with systemic steroids and two of the others received steroids to treat acute GVHD. Only two patients with catar acts (follow-up 43 and 47 months) did not take steroids. All patients given fractionated TBI received steroids, three for acute and two for chronic GVHD. The four patients without TBI have not developed cataracts, although two were given steroids for chronic GVHD (follow-up 10 and 24 months). A third patient took steroids for acute GVHD, but only for seven days.
Of the eleven patients with chronic GVHD, eight have symptomatic KCS (five single shot, two fractionated and one no TBI) and another (Patient 31), who received no TBI, has cor neal and conjunctival staining with reduced tear flow of Schirmers test, but is asympto matic. One other patient without chronic GVHD but who received fractionated TBI, has clinical KCS (Rose Bengal staining and reduced Schirmers test). Only two patients with chronic GVHD have no ocular problems (both single shot TBI). Two patients with chronic GVHD and KCS have developed more serious sequelae of dry eyes. Patient 20, aged 26 years, developed persistent corneal epithelial loss with corneal stromal thinning which resolved leaving widespread vas cularised corneal scars. Patient 32, aged 34 years, developed a sterile corneal ulcer.
A mild superior tarsal follicular reaction was seen in three patients, a further three had some superior tarsal scarring (all with a history of acute GVHD) and one patient suf fers recurrent episodes of episcleritis.
Discussion
Cataract formation after exposure to ionising radiation has been recognised since 1897. 2 Merriam and Focht3 estimated the minimal dose to produce a cataract in man was 2 Gy in a single dose, 4 Gy if given over three weeks to three months, and 5.5 Gy if given over longer than three months. However, they also point out that over the same time interval doses as high as 10-11 Gy have been given without cataract formation. Total body irradiation and chemotherapy is used as a conditioning regime p rior to BMT both to kill all host malignant cells and to suppress the host immune response and thus minimise rejection of the donor marrow. Our findings of an 83.3% incidence of cataracts after single shot TBI agrees with p reviously reported figures.4,5 Deeg et al., n re p ort a rela tive risk of developing cataract after single shot TBI 4.77 times greater than after frac tionated TBI or no TBI at all. They were surprised to find the incidence in patients who received fractionated TBI to be no greater than the 19% in p atients who had no TBI. We found no p atients with cataract after frac tionated TBI, although the longest follow-u p in this group was 18 months. Of the six patients who had no TBI, one developed Grade I PSCLO at the age of 61 years, which may therefore have been unrelated to the transplant. Significantly, it has been found that 50% of patients with cataract after single shot TBI need surgery with a median of six years post BMT compared to only 20% who had fractionated TBI and none who had no TBI.4 These figures suggest that as well as reducing the incidence of cataracts, frac tionated TBI may also reduce the clinical severity of the cataracts that do develo p .
Deeg et al.,<' also analysed factors other than radiation which may have contributed to the development of cataract. Significant factors were found to be acute and chronic GVHD, steroid use after Day 100 and initial diagnosis. There was a higher incidence in patients with acute lymphoblastic leukaemia (ALL) which did not appear to have been influenced by pre-transplant cranial irradia tion. It may, however, have been related to pre-transplant treatment with systemic steroids. A 52% incidence of PSCLO has been reported in survivors of ALL who had not undergone BMT. 7 The effect of long term use of systemic steroids on the formation of PSCLO was first re p orted by Black in 1960 in p atients with rheumatoid arthritis. R Cataracts were not seen if the duration of treatment was less than one year, but 11 % of those taking a moderate dose and 78% a high dose developed cataracts in 1--4 years, the incidence increasing the longer the duration of treatment. None of the patients were taking the huge doses needed in the treatment of GVHD often starting with 3 gm Methyl-Prednisolone daily, albeit usually with quick dosage reduction. Younger patients tend to develop cataracts at lower doses and within a shorter time period. 9 Within a follow-up p eriod of 23--42 months, four out of five p atients who received auto logous trans p lants with single shot TBI devel oped Grade I or II PSCLO. The five patients with cataracts after single shot TBI and allogeneic BMT who had been seen at a similar time p ost transplant (26--4 4 months) all had Grade IV PSCLO. All but one of these p atients had received steroids for chronic GVHD. Longer follow-u p is needed to draw any conclusions about the effects of systemic steroids after fractionated TBI, but Deeg re p orts that steroids are a significant factor, as the incidence of cataracts after fractionated TBI in those who had no steroids was only 9% .6
The Seattle Trans p lantation Group report that 55-90% (de p ending on initial diagnosis) of patients undergoing BMT survive with no recurrence of their disease. j() Acute GVHD develops within the first 100 days post trans p lantation p roducing an exanthematous der matitis, hepatitis and enteritis. Ten per cent also have ocular problems including prop tosis, cranial nerve palsies, intra-retinal haemorrhages and herpes simplex/z'lster infectionsll. However, the commonest finding in a group of patients in Seattle was of a cul ture negative haemorrhagic conjunctivitis, which proceeded to an exudative phase with ulceration of the superior tarsal conjunctiva and pseudomembrane formation on the inferior tarsal conjunctiva. This resolved leav ing characteristic scarring which was seen in three Cardiff patients, all of whom had a history of acute GVHD.
In 25-45% of long term survivors, chronic GVHD develops. 12 . 13,14 This occurs by defi nition more than 100 days post transplanta tion and may be a continuation of acute GVHD, follow acute GVHD or arise de novo. Most investigators believe that it represents an immunological process mediated by immu nocompetent donor lymphocytes reacting to genetically determined histocompatibility differences in the host.15 Several reports have shown an imbalance in both humoral and cell mediated immune regulation including hyper gammaglobulinaemia,13,\6 deposits of immu noglobulin and complement at the dermo epidermal junction of the skin, 17 and the pres ence of autoantibodies. 13 Clinically, chronic GVHD has similarities with autoimmune disorders such as systemic sclerosis, SLE, lichen planus and Sjogrens syndrome. Organs involved include the mouth, nose, eyes, liver, GI tract, lung, mus culoskeletal, haematologic and lymphoid systems. IS The most frequent ocular abnor mality is a Sjogren-like syndrome first described by Lawley et al., 19 and Gratwohl et at., 20 who also demonstrated lymphocyte and plasmacyte infiltration into the minor salivary glands identical to that of Sjogrens syndrome. Other reported findings in chronic GVHD include cicatricial lagophthalmos, sterile con junctivitis and uveitis. 21 In this study, 50% of patients who under went allogeneic BMT developed chronic GVHD, 81.8% of these with ocular involve ment of type and frequency comparable with previous reports.4,14,21,22 After autologous BMT, four patients (two single shot, one frac tionated and one no TBI) had clinical evi dence of reduced tear production in one or both eyes, but none of these patients was symptomatic. The patient who had no TBI with bilateral KCS at the age of 53 years has serology consistent with Sjogrens syndrome. Keratoconjunctivitis sicca may follow direct irradiation to the lacrimal apparatus. Parsons et at., 23 report severe dry eye problems in 19 patients who received direct irradiation of the orbit for orbital tumours, but say that most patients will tolerate doses in the range 3,000-4,000 cGy to the entire orbit without develop ing severe symptoms of a dry eye. It seems likely that orbital irradiation even at the dos age regimen used for marrow transplantation is a contributory factor to the development of KCS which can no longer be uniquely associ ated with allogeneic BMT and chronic GVHD,
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